The Application of Robotics to Aseptic Environmental Surface Monitoring - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Application of Robotics to Aseptic Environmental Surface Monitoring
This article presents a study of an aseptic environmental monitoring system for surface contamination at critical areas using a robot.


Pharmaceutical Technology



Table V: Wet swab efficiency (manual).
When the wetting agent was changed from distilled water to mixture 0.1%Tween 80 in distilled water, the rate of recovery of M. luteus improved, but complete recovery could not be achieved. Increasing the number of back-and-forth swabbing motions actually resulted in a decrease in recovery rates (see Table IV). A comparison of manual sampling to robotic sampling under the same test conditions showed a lower recovery rate associated with manual swabbing. The recovery efficiency observed with manual swabbing was approximately 20%. Additionally, far more variability in recovery was observed with manual swabbing as compared with robotic swabbing (see Table V).

Discussion


Figure 3
Wet-swab sampling often is avoided in aseptic operations because of concerns about residual moisture that might encourage microbial proliferation. However, the experimental data clearly confirm that moistened swabs are much more effective in terms of contamination recovery. We observed that using surfactant Tween 80 resulted in improved recovery as compared with using plain distilled water. It has been reported that dry, agglomerated microorganisms can strongly adhere to surfaces; therefore, it is logical that moistened swabs, particularly with the addition of a surfactant, can recover this contamination from surfaces. Given the benefits of using moistened swabs, surface monitoring could best be executed just after the completion of an aseptic production operation or in advance of breaking the aseptic condition of the isolator or RABS. As demonstrated in Table IV, even when using the robot for sampling, better efficiency of recovery was observed with B. atrophaeus than with M. luteus.


Figure 4
The most significant difference between these two test organisms is that M. luteus is a vegetative cell and B. atrophaeus is a spore. The sizes are also different. The size of the former is ~0.7–0.8 µm, and the latter has a diameter of ~1 × 2–3 µm, although it is unknown to what degree the size of the organism plays a role in recovery efficiency. Consequently, the authors believe the primary considerations in recovery efficiency differences between these two organisms are: spores as compared with vegetative cells, and the agglomeration and adherence to the test coupon. The authors also believe the physical composition of the swab tip may play a role in recovery efficiency. Additional investigation is needed to determine which factors have the greatest influence on recovery rates.


Figure 5
Recovery efficiency was influenced by the time allowed for soaking the swab tip with the wetting agent. Wetting the swab immediately before use does not appear to allow sufficient time for saturation to occur. The authors believe that wetting immediately before use results in a swab that is completely dry before the completion of the swabbing action and therefore less efficient. In this case, the full benefits of wet swabbing are not realized. When the swab tip is allowed to soak overnight before use, however, the swab retains moisture from beginning to end of the swabbing action. The fully saturated swab gave a superior recovery efficiency of microorganisms. Therefore, the degree of wetness of the swabs plays a critical role in recovery efficiency.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here